Dr. McKay on the Utility of Radium-223 in the Treatment of mCRPC

Video

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the utility of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer (mCRPC).

When considering treatment for patients with mCRPC, looking at real-world data is important, says McKay. It is becoming clear understanding is that mCRPC is probably an undertreated disease, adds McKay. Many patients may receive a first-line therapy for mCRPC but many never receive second- or third-line therapy. Some agents have been shown to improve overall survival (OS) in this patient population, such as radium-223.

The first-step for any practicing oncologist is to treat the disease, says McKay. There may be various reasons to not treat a patient, but some of the available drugs have proven to be life-prolonging. Agents are moving into the castration-sensitive space as well, which is actually resulting in decreased options for those with mCRPC, says McKay. Radium-223 is a good agent to use in patients with mCRPC who have bone metastases, concludes McKay.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD